Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Upfront Window in Metastatic Rhabdomyosarcoma
NCT00003955Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Sep 1999
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of irinotecan in rhabdomyosarcoma (RMS), sponsored by Children's Oncology Group. Started Sep 1999; status: completed.
02
Drugs
irinotecan
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT00003955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003955.